IPCA Laboratories Ltd launches Diulcus to address Diabetic Foot Ulcer (DFU) in India

-

 


by Samiksha 

- Diulcus, developed by NovaLead Pharma, shows promising results in clinical trials with a 77.20% ulcer closure rate

- Approved by CDSCO and partially funded by BIRAC

Mumbai, August 16, 2024: As per the ICMR-INDIAB (2023) study, 10 crore people in India suffer from diabetes, with an additional 13.6 crore people affected by pre-diabetes. This significant health concern positions India to become the diabetes capital of the world by 2030.

In response to this serious healthcare challenge, IPCA Laboratories Ltd proudly announces the launch of Diulcus, a novel product aimed at addressing the challenges of Diabetic Foot Ulcer (DFU) in the Indian market. Diulcus, developed by NovaLead Pharma Pvt Ltd, a pioneer in drug repurposing, represents a significant advancement in the management of DFU. The product has received approval from the Central Drugs Standard Control Organization (CDSCO) and was partially funded by the Biotechnology Industry Research Assistance Council (BIRAC), a Government of India enterprise.

The launch event was graced by esteemed personalities, including Sri. Premchand Godha, Sri AK Jain, Dr. Anil Pareek, Sri Sunil Ghai, and Sri. Supreet Deshpande.

During phase 3 trials in India, Diulcus demonstrated remarkable efficacy, with a 60.3% ulcer closure rate within three months of treatment. Remarkably, patients continued to show an ulcer closure rate of 77.20% over six months, even after stopping treatment at three months. These results are among the best observed for any pharmaceutical preparation used in DFU treatment.

Mr. Premchand Godha, Executive Chairman of IPCA Laboratories Ltd, expressed his enthusiasm about the launch, stating, "With over 15% of diabetic patients suffering from DFU at least once in their lifetime, DFU is the most prevalent complication caused by chronic diabetes. The approval of this patented repurposed drug is significant because DFU is the leading cause for lower limb amputations globally. We are delighted to partner with NovaLead Pharma Pvt Ltd through an IP licensing arrangement to bring Diulcus® for DFU patients in India. It demonstrates IPCA’s commitment towards the patients suffering from unmet medical need and its focus on the diabetes therapy." Diulcus will be made available to the patients of DFU by Ipca Laboratories Ltd. (Ipca) through an exclusive IP licensing arrangement with NovaLead for Indian starting August 2024.

For further details on the product, please consult your physician or write to savethefoot@ipca.com.

About Diabetic Foot Ulcer (DFU): Over 537 million adults are living with diabetes globally and the number is predicted to rise to 643 million by 2030. About 15% of diabetics suffer from DFU, at least once in lifetime, with 25% of DFUs eventually requiring amputation. DFU is a leading cause of lower extremity amputation. The five-year mortality post amputation is 46%. DFU is a serious disease with very limited drug options and very high cost of treatment.

About Diulcus@ (Esmolol Ilydrochloride)D :iulcus@ is a prescription medicine used to treat people with diabetic foot ulcer with no clinical infection. Infected DFUs need to be first treated for infection if existing and then put on Diulcus@ treatment for wound closure. A doctor will perform independent assessment of DFU extent to determine the dose to be applied topically on the patient's DFU. Treating clinicians are advised to refer to the full prescribing information of Diulcus@.

About Ipca Laboratories Ltd (Ipca):Ipca is a fully integrated pharmaceutical company with a strong thrust on exports. Ipca is vertically integrated and produces Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs).


Comments

Post a Comment

Popular posts from this blog

Are ‘Unseen Forces’ Really Driving Political Vendetta Against Darwin Platform Chief Ajay Harinath Singh?

-
Image
by samikha   Mumbai, May, 2024: The scion of Lord Shri Ram's lineage, Darwin Platform Group of Companies (DGPC) Founder and Chairman Ajay Harinath Singh has found himself targeted by unseen forces with vested interests. Retaliating to these ‘unseen forces’ the Darwin Platform Chief emphasized that life threats and malicious campaigns, resulting from political vendetta make him more determined to fight the battle and expose them.  The whispers of a conspiracy began years ago, fueled by jealousy and fear of his growing influence in the 2000s. Coming from a Royal family of Sultanpur (Uttar Pradesh), his popularity in the state and Maharashtra unnerved many political parties that used to govern. Aligned with sacred lineage, his passion for nation-building and Hindutva made him popular among people and the BJP, however, this antagonized Congress and their current allies. Questions are many- Was the Congress party, in its bid to maintain its hold on power, orchestrating a campaign t...
Read more

Dell Technologies Reimagines Work with New PCs, Monitors and Software Experiences

-
Image
     by Samiksha   ·         Work smarter than ever before with the industry’s most intelligent [i] , secure [ii]  and sustainable [iii]  business PCs ·          5G-capable PCs and Microsoft Teams certified displays unlock enhanced connectivity and collaboration ·          Dell elevates sustainability standards with first commercial  PCs to use bioplastics from tree waste ·         Built-in low blue light and security technology enhance and secure the customer experience Bangalore, India -January, 2021;   Dell Technologies (NYSE:DELL) unveiled new products and software that reimagine work so anyone can perform at their best. With a new portfolio of intelligent, collaborative and sustainable devices, Dell is transforming work experiences to give people greater flexibility to work from anywhere. “Peopl...
Read more

‘Dennkur’ The World’s First Curcumin Pastille For Oral Health Care Launched

-
Image
The World’s First Curcumin Pastille For Oral Health Care Launched In Mumbai   Mumbai, March 07:  For the first time in the field of dentistry, Curcumin – a concentrated extract of turmeric with its excellent therapeutic effects has made its way as a pastille for preventive oral health care. This first of its kind pastille christened ‘Dennkur’ was launched in Mumbai yesterday and will be available with dentists across the country. The product has been introduced by Denteks, leading experts in dental technology of which Dr. Nirupam K Doctor and Dr. Lalit K Chokhani launched the breakthrough product in the presence of several eminent doctors and researchers. The 100 per cent ayurvedic and sugar-free medicine is backed by clinical and social trials and has proved to be highly effective in preventive and therapeutic applications in a variety of oral diseases including bleeding gums, receding gums, gingivitis, and periodontitis, among others. “...
Read more